A global biotechnology company wanted to forecastmarket potential for their oral TKI inhibitor of the HER2 protein, which had been approved for oncology indication for all major markets.
Viscadia was asked to design and build an epidemiology-based patient flow model to construct a market landscape and assess product potential across 22 different markets around the world, while also incorporating regional nuances specific to several key markets.
Designed and built a comprehensive patient flow forecast model, allowing in-depth tracking of patient metrics (such as naïve and experienced patients, and more) across multiple lines of therapy
Constructed an easy-to-use event module to model the impact of new launches and indication approvals on market, product, and patient trends
Engaged with stakeholders to understand strategic imperatives and developed a forecasting framework that could scale across geographies
Automated the aggregation of 22 regional models with the global forecast to facilitate decision making at headquarters
Performed deep-dives and set up analytical processes to continuously refine key forecasting assumptions, including projections for SKU-level demand and bolus patients
Equipped the regional and global models with the functionality to simulate what-if scenarios, review KPIs, and assess key forecast drivers